Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios in Distinguishing Lung Cancer in People with HIV

Table 2

Factors associated with lung cancer among PLWH.

Characteristic	Crude RR (95% CI)	p Value	Adjusted RR (95% CI)	p Value
Patient on ART
No	Ref		Ref
Yes	0.12 (0.04, 0.33)	<0.001	1.53 (0.30, 7.25)	0.608
Previous TB treatment
No	Ref		Ref
Yes	4.28 (1.69, 10.84)	0.002	1.83 (0.46, 7.25)	0.388
Cough
No	Ref		Ref
Yes	11.57 (3.77, 35.48)	<0.001	2.29 (0.37, 14.12)	0.374
Weight loss
No	Ref		Ref
Yes	16.09 (5.74, 45.12)	<0.001	1.27 (0.10, 16.02)	0.852
Chest pain
No	Ref
Yes	18.94 (5.29, 67.91)	<0.001
Laboratory results
White blood cell count	1.13 (1.06, 1.19)	<0.001	1.95 (0.35, 10.76)	0.442
Neutrophil count	1.15 (1.08, 1.22)	<0.001	0.50 (0.10, 2.57)	0.407
Lymphocyte count	0.23 (0.11, 0.50)	<0.001	0.27 (0.02, 3.53)	0.320
Hemoglobin level	0.57 (0.46, 0.70)	<0.001	0.74 (0.50, 1.08)	0.121
Creatinine	0.97 (0.96, 0.99)	0.001	0.99 (0.97, 1.01)	0.177
NLR	1.13 (1.07, 1.19)	<0.001	0.99 (0.73, 1.36)	0.959
PLR	1.003 (1.001, 1.004)	<0.001	1.00 (0.10, 1.01)	0.377

ART, antiretroviral therapy; NLR, neutrophil–leucocyte ratio; PLR, platelet–leucocyte ratio. Bold p-values indicate a statistically significant result.